Janux Therapeutics (JANX) Receivables - Accured: 2021-2025
Historic Receivables - Accured for Janux Therapeutics (JANX) over the last 5 years, with Sep 2025 value amounting to $6.3 million.
- Janux Therapeutics' Receivables - Accured rose 40.00% to $6.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.3 million, marking a year-over-year increase of 40.00%. This contributed to the annual value of $5.4 million for FY2024, which is 145.45% up from last year.
- As of Q3 2025, Janux Therapeutics' Receivables - Accured stood at $6.3 million, which was up 10.53% from $5.7 million recorded in Q2 2025.
- In the past 5 years, Janux Therapeutics' Receivables - Accured registered a high of $28.0 million during Q3 2021, and its lowest value of $3,000 during Q2 2021.
- Over the past 3 years, Janux Therapeutics' median Receivables - Accured value was $4.5 million (recorded in 2024), while the average stood at $3.8 million.
- Data for Janux Therapeutics' Receivables - Accured shows a peak YoY increase of 9,900.00% (in 2022) and a maximum YoY decrease of 98.93% (in 2022) over the last 5 years.
- Janux Therapeutics' Receivables - Accured (Quarterly) stood at $200,000 in 2021, then surged by 250.00% to $700,000 in 2022, then skyrocketed by 214.29% to $2.2 million in 2023, then soared by 145.45% to $5.4 million in 2024, then soared by 40.00% to $6.3 million in 2025.
- Its last three reported values are $6.3 million in Q3 2025, $5.7 million for Q2 2025, and $5.6 million during Q1 2025.